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Supplementary Information for: Analyses of 7,635 patients with colorectal cancer using independent training and validation cohorts show that rs9929218 in CDH1 is a prognostic marker of survival.
Supplementary References
The Health Professionals Follow-up Study (1), the Nurses' Health Study (2-4), the Physicians' Health Study (5) , the VITamins And Lifestyle Study (6) , the Women's Health Initiative (7) , and, the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (8, 9) . Protocols for assessing survival in these studies (1,4,6,10-12). A full listing of WHI investigators can be found at:
https://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/W HI%20Investigator%20Short%20List.pdf. 
Supplementary Tables
Supplementary Table S1 Survival analyses were carried out under the model that was found to best fit the training phase data: rs16892766 -dominant; rs9929218 and rs10795668 -recessive (unadjusted). Note -rs9929218 was directly genotyped in all of the studies. rs16892766 and rs10795668 were directly genotyped in some studies and imputed in others -so numbers represent the best calls. 
